Austar Lifesciences Limited provided earnings guidance for the six months ended 30 June 2022. The Group is expected to record a profit attributable to the owners of the Company of not less than RMB 43 million for the six months ended 30 June 2022, as compared to the profit attributable to the owners of the Company of approximately RMB 218 million for the six months ended 30 June 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 HKD | -8.79% | +9.21% | -46.79% |
03-26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-46.79% | 54.45M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
+13.67% | 25.02B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022